MABgene

Sanofi and the LFB have entered into a partnership agreement in 2010 and put in place a joint bioproduction platform, called MAbLaunch, combining LFB BIOMANUFACTURING (LFB Group) and BioLaunch (Sanofi) capabilities in the field of contract development and manufacturing services for biopharmaceuticals.
MAbLaunch acts as a “one-stop shop” and aims at providing the widest range of integrated CMO services to customers using respective industrial capacities in the most flexible manner. With considerable expertise in process development and manufacturing of monoclonal antibodies using mammalian cell culture technologies, MAbLaunch offer starts with cell line development, going through process development and scale up, continuing into manufacturing of clinical and commercial batches at large scale (up to 3x 10,000L) and Fill&Finishing of the drug product.

MAbLaunch: the advantages of a large pharma… combined with flexible CMO services

Click here to download MAbLaunch brochure: http://www.terrapinn.com/2011/european-antibody-congress/data/mablaunch.pdf